| Twin Harbors Optical | |
|
207 S Chehalis St, Aberdeen, WA 98520-2945 | |
| (360) 533-2020 | |
| (360) 533-1978 |
| Full Name | Twin Harbors Optical |
|---|---|
| Type | Facility |
| Speciality | Ophthalmology |
| Location | 207 S Chehalis St, Aberdeen, Washington |
| Accepts Medicare Assignments | Medicare enrolled and accepts medicare insurance. Providers at this facility may prescribe medicare part D drugs. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1962690701 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 152W00000X | Optometrist | OD60310191 (Washington) | Secondary |
| 207W00000X | Ophthalmology | MD28344 (Washington) | Primary |
| Provider Name | Susan Ruyle |
|---|---|
| Provider Type | Practitioner - Ophthalmology |
| Provider Identifiers | NPI Number: 1215969878 PECOS PAC ID: 2163415027 Enrollment ID: I20040513000485 |
News Archive
Doctors treat and heal patients, but they are seldom seen as people who may themselves require care or accommodation. Medics with disabilities are now calling for a paradigm shift in this mindset to make medical education and the profession more inclusive.
The expansion of Medicaid coverage for low-income adults permitted by the Affordable Care Act was associated with a six percent reduction in total opioid overdose deaths nationally, according to new research from NYU Grossman School of Medicine and University of California, Davis.
Scientists have moved a step closer to correcting some unhealthy gene mutations with diet, according to a new research report appearing in the April 2012 issue of the journal GENETICS.
Genzyme Corporation announced results today from its CLASSIC I phase 3 trial comparing Clolar® (clofarabine) in combination with the chemotherapy agent cytarabine (ara-c) to cytarabine plus placebo in relapsed-refractory adult acute myeloid leukemia (AML).
In an important development for the health of elderly people, University of Liverpool researchers have developed a new method to target bone growth.
› Verified 8 days ago
| Provider Name | Joshua Douglas Pratt |
|---|---|
| Provider Type | Practitioner - Optometry |
| Provider Identifiers | NPI Number: 1457621856 PECOS PAC ID: 8022271543 Enrollment ID: I20130205000503 |
News Archive
Doctors treat and heal patients, but they are seldom seen as people who may themselves require care or accommodation. Medics with disabilities are now calling for a paradigm shift in this mindset to make medical education and the profession more inclusive.
The expansion of Medicaid coverage for low-income adults permitted by the Affordable Care Act was associated with a six percent reduction in total opioid overdose deaths nationally, according to new research from NYU Grossman School of Medicine and University of California, Davis.
Scientists have moved a step closer to correcting some unhealthy gene mutations with diet, according to a new research report appearing in the April 2012 issue of the journal GENETICS.
Genzyme Corporation announced results today from its CLASSIC I phase 3 trial comparing Clolar® (clofarabine) in combination with the chemotherapy agent cytarabine (ara-c) to cytarabine plus placebo in relapsed-refractory adult acute myeloid leukemia (AML).
In an important development for the health of elderly people, University of Liverpool researchers have developed a new method to target bone growth.
› Verified 8 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Twin Harbors Optical 207 S Chehalis St, Aberdeen, WA 98520-2945 Ph: (360) 533-2020 | Twin Harbors Optical 207 S Chehalis St, Aberdeen, WA 98520-2945 Ph: (360) 533-2020 |
News Archive
Doctors treat and heal patients, but they are seldom seen as people who may themselves require care or accommodation. Medics with disabilities are now calling for a paradigm shift in this mindset to make medical education and the profession more inclusive.
The expansion of Medicaid coverage for low-income adults permitted by the Affordable Care Act was associated with a six percent reduction in total opioid overdose deaths nationally, according to new research from NYU Grossman School of Medicine and University of California, Davis.
Scientists have moved a step closer to correcting some unhealthy gene mutations with diet, according to a new research report appearing in the April 2012 issue of the journal GENETICS.
Genzyme Corporation announced results today from its CLASSIC I phase 3 trial comparing Clolar® (clofarabine) in combination with the chemotherapy agent cytarabine (ara-c) to cytarabine plus placebo in relapsed-refractory adult acute myeloid leukemia (AML).
In an important development for the health of elderly people, University of Liverpool researchers have developed a new method to target bone growth.
› Verified 8 days ago